| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 09/12/2001 | EP1132086A2 Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure |
| 09/12/2001 | EP1131464A1 Method for screening for substances which are activators, inhibitors or binders of pkb by the use of a substrate peptide and the use of the substrate peptide |
| 09/12/2001 | EP1131449A1 Method for identifying inhibitors of ipc synthase |
| 09/12/2001 | EP1131445A1 Human phospholipases |
| 09/12/2001 | EP1131443A2 Human hydrolase proteins |
| 09/12/2001 | EP1131428A2 Immunoglobulin superfamily proteins |
| 09/12/2001 | EP1131426A2 Mage-10 or mage-8 derived hla-a2.1-binding oligopeptides |
| 09/12/2001 | EP1131417A2 Engineered cytotoxic ribonuclease |
| 09/12/2001 | EP1131410A1 Bioengineered tissue constructs and methods for producing and using them |
| 09/12/2001 | EP1131351A2 Peptides that modulate the interaction of b class ephrins and pdz domains |
| 09/12/2001 | EP1131350A1 Egf-like nucleic acids and polypeptides and uses thereof |
| 09/12/2001 | EP1131349A2 Potassium channel interactors and uses therefor |
| 09/12/2001 | EP1131340A2 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis |
| 09/12/2001 | EP1131334A1 Use of core 2 glcnac transferase inhibitors in treating inflammation |
| 09/12/2001 | EP1131322A2 Dihydropyridine compounds and methods of use |
| 09/12/2001 | EP1131315A1 Polyhydroxylated heterocyclic derivatives as anti-coagulants |
| 09/12/2001 | EP1131308A1 New piperazine and piperidine compounds |
| 09/12/2001 | EP1131304A1 N- 4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
| 09/12/2001 | EP1131301A1 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof |
| 09/12/2001 | EP1131295A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists |
| 09/12/2001 | EP1131294A1 Quinoline derivatives as nk-2 and nk-3 receptor ligands |
| 09/12/2001 | EP1131291A1 4-aroyl-piperidin-ccr-3 receptor antagonists iii |
| 09/12/2001 | EP1131290A1 Piperidine ccr-3 receptor antagonists |
| 09/12/2001 | EP1131288A1 Pyrrolidine derivatives-ccr-3 receptor antagonists |
| 09/12/2001 | EP1131099A2 Noninvasive vascular therapy |
| 09/12/2001 | EP1131097A1 Anti-icam-r antibody-induced apoptosis |
| 09/12/2001 | EP1131085A2 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration |
| 09/12/2001 | EP1131083A1 Treatment of tumors by administration of growth hormone releasing compounds and their antagonists |
| 09/12/2001 | EP1131076A1 Method for treating a patient with neoplasia by treatment with an anthracycline antibiotic |
| 09/12/2001 | EP1131069A1 Method for treating a patient with neoplasia by treatment with a platinum coordination complex |
| 09/12/2001 | EP1131067A1 Composition and use of rar antagonists for promoting chondrogenesis |
| 09/12/2001 | EP1131062A1 Injectable propofol formulations |
| 09/12/2001 | EP1131059A1 Dry powder for inhalation |
| 09/12/2001 | EP1131037A1 Process for the manufacture of liquid filled capsules |
| 09/12/2001 | EP1032424B1 Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor |
| 09/12/2001 | EP0891354B1 N-aminoalkyldibenzofurancarboxamides as dopamine receptor subtype specific ligands |
| 09/12/2001 | EP0832066B1 Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors |
| 09/12/2001 | EP0822826B1 Nitrosylated neuropeptides |
| 09/12/2001 | EP0820450B1 N-substituted azaheterocyclic carboxylic acids and alkylesters thereof |
| 09/12/2001 | EP0809627B1 Novel borneol derivatives, methods of manufacturing them, and their pharmaceutical use |
| 09/12/2001 | EP0790987B1 Aminotetrazole derivatives useful as nitric oxide synthase inhibitors |
| 09/12/2001 | EP0749424B1 Naphthalene derivatives as prostaglandin i2 agonists |
| 09/12/2001 | EP0682514B1 Use of topical anesthetics for the manufacture of a medicament for the treatment of bronchial asthma |
| 09/12/2001 | EP0630240B1 Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (gaba) agonists |
| 09/12/2001 | EP0586474B1 Peptide nucleic acids |
| 09/12/2001 | CN1312810A Substituted 1,8-naphthyridin-4(1H)-ones as phosphodiesterase 4 inhibitors |
| 09/12/2001 | CN1312807A Inhibitors of glycogen synthase kinase 3 |
| 09/12/2001 | CN1312806A Prodrugs of proton pump inhibitors |
| 09/12/2001 | CN1312805A Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| 09/12/2001 | CN1312802A Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents |
| 09/12/2001 | CN1312800A Therapeutic biaryl derivatives |
| 09/12/2001 | CN1312799A Bispiperidines as antithrombotic agents |
| 09/12/2001 | CN1312724A TNF-drvived peptides of use in treating oedema |
| 09/12/2001 | CN1312719A Pharmaceutical Composition |
| 09/12/2001 | CN1312717A Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders |
| 09/12/2001 | CN1312716A Use of optically pure (-)-norcisapride in treatment of apnea, bulimta and other disorders |
| 09/12/2001 | CN1312715A Antihypersensitive combination of valsartan and calcium channel blocker |
| 09/12/2001 | CN1312714A Pharmaceutical composition containing lipase inhibitors and chitosan |
| 09/12/2001 | CN1312713A Pharmaceutical compositions containing lipase inhibitors |
| 09/12/2001 | CN1312712A Therapeutic composition based on flavonoids for use in treatment of tumours with cytotoxic agents |
| 09/12/2001 | CN1312704A Incorporation of exogenous lact'c bacteria into oral microflora |
| 09/12/2001 | CN1312372A Intocostrin regulation area and nucleotide series determination and method used thereof |
| 09/12/2001 | CN1312254A Novel nucleoside |
| 09/12/2001 | CN1312116A Liufukang oral liquid for supporting chemotherapy and radiotherapy of terminal cancer and its preparation method |
| 09/12/2001 | CN1312090A Chinese medicine for promoting height and intelligence growth |
| 09/12/2001 | CN1070866C Superagonists and antagonists and superantagonists of H IL-6, and 3-D modelling method for their selection |
| 09/12/2001 | CN1070849C Enzyme inhibitors |
| 09/12/2001 | CN1070699C Topical composition comprising N-acetye-L-cysteine |
| 09/11/2001 | US6288306 Methods of selecting plants, plant tissue or plant cells resistant to a protoporphyrinogen oxidase inhibitor |
| 09/11/2001 | US6288277 Drugs, antiarthritic agants, antihistamines for treatment of asthma |
| 09/11/2001 | US6288267 Thioamide derivatives |
| 09/11/2001 | US6288234 Fluorinated heterocyclic amido amine compounds as drugs |
| 09/11/2001 | US6288231 Peptide-containing α-ketoamide cysteine and serine protease inhibitors |
| 09/11/2001 | US6288123 Therapeutic guanidines |
| 09/11/2001 | US6288120 Prevention of loss and restoration of bone mass by certain prostaglandin agonists |
| 09/11/2001 | US6288118 Therapies for treating pulmonary diseases |
| 09/11/2001 | US6288111 Combination cisplatin/tamoxifen therapy for human cancers |
| 09/11/2001 | US6288110 Pharmaceutical compositions comprising disulfiram |
| 09/11/2001 | US6288107 Sulfatase inhibitors |
| 09/11/2001 | US6288105 Antithrombotic agents |
| 09/11/2001 | US6288104 Administering seretonin uptake inhibitors to treat depression, psychological and psychiatric disorders with an anxiety component, alcohol and drug dependence, bulimia nervosa and obsessive-compulsive disorders |
| 09/11/2001 | US6288103 Monocyte chemoattractant proteins antagonist such as n-(3-chlorophenylsulphonyl)indole-2-carboxylic acid; antiinflammatory agents |
| 09/11/2001 | US6288100 Benzimidazole derivatives |
| 09/11/2001 | US6288096 Thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives |
| 09/11/2001 | US6288092 Triaryl compounds |
| 09/11/2001 | US6288090 Pharmaceutical composition |
| 09/11/2001 | US6288084 Administering comounds such as 4-(4-chlorophenyl)-1-(4-(3-methoxyphenyl)-4-(3-pyridinyl)-3 -butenyl)piperidin-4-ol to treat diseases associated with aberrant leukocyte recruitment and/or activation |
| 09/11/2001 | US6288083 Chemokine receptor antagonists and methods of use therefor |
| 09/11/2001 | US6288077 2,3-methano-amino acid compounds |
| 09/11/2001 | US6288069 Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue |
| 09/11/2001 | US6288062 Interleukin and tumor necrosis factor inhibitors; antiinflammatory agents; rheumatic diseases; antiarthritic agents; respiratory system disorders |
| 09/11/2001 | US6288060 Corticotropin releasing factor antagonists; anxiolytic, antidepressant, antiinflammatory agents; eating disorders |
| 09/11/2001 | US6288056 Intermittent claudication therapeutic drugs comprising pyrroloazepines |
| 09/11/2001 | US6288055 Analgesic agents |
| 09/11/2001 | US6288050 Steroid sulfatase inhibitors and methods for making and using the same |
| 09/11/2001 | US6288037 C-terminally modified pentapeptides containing valine and aspartic acid |
| 09/11/2001 | US6288032 Polypeptides for osteoporosis and other bone disorder treatment |
| 09/11/2001 | US6288029 Template assembled synthetic peptide effective to treat respiratory system disorders |
| 09/11/2001 | US6288028 BPC peptide salts with organo-protective activity, the process for their preparation and their use in therapy |
| 09/11/2001 | US6287816 BMP-9 compositions |